TY  - JOUR
AU  - Goss, Glenwood D
AU  - Cobo, Manuel
AU  - Lu, Shun
AU  - Syrigos, Konstantinos
AU  - Lee, Ki Hyeong
AU  - Göker, Erdem
AU  - Georgoulias, Vassilis
AU  - Isla, Dolores
AU  - Morabito, Alessandro
AU  - Min, Young J
AU  - Ardizzoni, Andrea
AU  - Bender, Shaun
AU  - Cseh, Agnieszka
AU  - Felip, Enriqueta
PY  - 2021
DO  - 10.1016/j.eclinm.2021.100940
UR  - http://hdl.handle.net/10668/18065
T2  - EClinicalMedicine
AB  - LUX-Lung 8 was a randomised, controlled, phase 3 study comparing afatinib and erlotinib as second-line treatment of patients with advanced squamous cell carcinoma (SCC) of the lung. We report the final overall survival (OS) and safety analyses of...
LA  - en
PB  - Elsevier
KW  - Afatinib
KW  - ERBB
KW  - Non-small cell lung cancer
KW  - Second-line
KW  - Squamous cell lung carcinoma
KW  - Erlotinib Hydrochloride
KW  - Carcinoma, Squamous Cell
KW  - Lung
KW  - Immunotherapy
KW  - Disease Progression
KW  - Mutation
TI  - Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung: Final analysis of the randomised phase 3 LUX-Lung 8 trial.
TY  - research article
VL  - 37
ER  -